Skip to content

AYTU BIOPHARMA, INC: 10-Q filed 2025-02-12

What AYTU BIOPHARMA, INC reported in its quarterly report filed 2025-02-12 (fiscal Q2 2025): 49 published measures, 140 facts as tagged in accession 0001437749-25-003568.

This filing

Form
10-Q (quarterly report)
Filed
2025-02-12
Fiscal period
fiscal Q2 2025
Accession
0001437749-25-003568 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All AYTU BIOPHARMA, INC filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2024-12-31116,227,000USD
At 2024-06-30118,095,000USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2024-12-3130,765,000USD
At 2024-09-3029,826,000USD
At 2024-06-3027,716,000USD
At 2023-12-3132,853,000USD
At 2023-09-3032,167,000USD
At 2023-06-3039,357,000USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2024-12-3120,398,000USD
At 2024-06-3020,006,000USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2024-10-01 to 2024-12-31788,000USD92
2024-07-01 to 2024-12-312,262,000USD184
2024-07-01 to 2024-09-301,474,000USD92
2023-10-01 to 2023-12-31-220,000USD92
2023-07-01 to 2023-12-31-8,340,000USD184
2023-07-01 to 2023-09-30-8,120,000USD92

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2024-07-01 to 2024-12-311,715,000USD184
2023-07-01 to 2023-12-31-346,000USD184

Contract revenue excluding tax

Revenue from customer contracts excluding assessed taxes under this specific taxonomy concept. It is not automatically comparable to older revenue tags.

PeriodValueUnitDays
2024-10-01 to 2024-12-3116,221,000USD92
2024-07-01 to 2024-12-3132,795,000USD184
2023-10-01 to 2023-12-3118,748,000USD92
2023-07-01 to 2023-12-3136,565,000USD184

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2024-07-01 to 2024-12-31-1,849,000USD184
2023-07-01 to 2023-12-31-2,860,000USD184

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2024-07-01 to 2024-12-31526,000USD184
2023-07-01 to 2023-12-31-250,000USD184

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2024-12-31-317,711,000USD
At 2024-06-30-319,973,000USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2024-10-01 to 2024-12-316,132,060shares92
2024-07-01 to 2024-12-316,100,204shares184
2023-10-01 to 2023-12-315,517,670shares92
2023-07-01 to 2023-12-315,499,951shares184

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2024-10-01 to 2024-12-318,485,112shares92
2024-07-01 to 2024-12-318,782,794shares184
2023-10-01 to 2023-12-315,517,670shares92
2023-07-01 to 2023-12-315,499,951shares184

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2024-10-01 to 2024-12-310.13USD/shares92
2024-07-01 to 2024-12-310.37USD/shares184
2023-10-01 to 2023-12-31-0.04USD/shares92
2023-07-01 to 2023-12-31-1.52USD/shares184

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-0.26USD/shares92
2024-07-01 to 2024-12-31-0.41USD/shares184
2023-10-01 to 2023-12-31-0.04USD/shares92
2023-07-01 to 2023-12-31-1.52USD/shares184

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-283,000USD92
2024-07-01 to 2024-12-31122,000USD184
2023-10-01 to 2023-12-31780,000USD92
2023-07-01 to 2023-12-31780,000USD184

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2024-12-31516,000USD
At 2024-06-30693,000USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2024-07-01 to 2024-12-31324,000USD184
2023-07-01 to 2023-12-311,432,000USD184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2024-10-01 to 2024-12-31-1,695,000USD92
2024-07-01 to 2024-12-31-2,625,000USD184
2023-10-01 to 2023-12-313,146,000USD92
2023-07-01 to 2023-12-312,279,000USD184

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2024-12-3164,048,000USD
At 2024-06-3062,228,000USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2024-12-3111,699,000USD
At 2024-06-3010,314,000USD

Net finite-lived intangible assets

Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.

PeriodValueUnitDays
At 2024-12-3149,958,000USD
At 2024-06-3052,453,000USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2024-12-3125,403,000USD
At 2024-06-3023,526,000USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2024-10-01 to 2024-12-3112,481,000USD92
2024-07-01 to 2024-12-3125,396,000USD184
2023-10-01 to 2023-12-3111,457,000USD92
2023-07-01 to 2023-12-3125,362,000USD184

Net inventory

Inventory carrying amount after applicable valuation and LIFO reserves. It does not establish realizable selling proceeds or inventory turnover without other inputs.

PeriodValueUnitDays
At 2024-12-3111,085,000USD
At 2024-06-3012,141,000USD

Gross profit

Revenue less the costs directly attributed to the goods or services sold. It precedes other operating expenses and is not net income.

PeriodValueUnitDays
2024-10-01 to 2024-12-3110,786,000USD92
2024-07-01 to 2024-12-3122,771,000USD184
2023-10-01 to 2023-12-3114,603,000USD92
2023-07-01 to 2023-12-3127,641,000USD184

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2024-10-01 to 2024-12-31522,000USD92
2024-07-01 to 2024-12-31948,000USD184
2023-10-01 to 2023-12-31521,000USD92
2023-07-01 to 2023-12-311,116,000USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2024-12-316,169,681shares
At 2024-06-305,972,638shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2024-12-31348,475,000USD
At 2024-06-30347,688,000USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

PeriodValueUnitDays
At 2024-12-311,178,000USD
At 2024-06-30829,000USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

PeriodValueUnitDays
At 2024-12-311,288,000USD
At 2024-06-301,289,000USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

PeriodValueUnitDays
At 2024-12-311,167,000USD
At 2024-06-302,818,000USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

PeriodValueUnitDays
At 2024-12-31651,000USD
At 2024-06-302,125,000USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2024-12-3149,958,000USD
At 2024-06-3052,453,000USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-12-311,522,000USD
At 2024-06-302,185,000USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2024-12-315,045,000USD
At 2024-06-304,529,000USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2024-12-3139,372,000USD
At 2024-06-3038,143,000USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2024-10-01 to 2024-12-31382,000USD92
2024-07-01 to 2024-12-311,880,000USD184
2023-10-01 to 2023-12-311,399,000USD92
2023-07-01 to 2023-12-31-6,074,000USD184

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2024-10-01 to 2024-12-31788,000USD92
2024-07-01 to 2024-12-312,262,000USD184
2023-10-01 to 2023-12-31-220,000USD92
2023-07-01 to 2023-12-31-8,340,000USD184

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2024-10-01 to 2024-12-314,449,000USD92
2024-07-01 to 2024-12-319,574,000USD184
2023-10-01 to 2023-12-314,800,000USD92
2023-07-01 to 2023-12-3111,095,000USD184

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

PeriodValueUnitDays
2024-10-01 to 2024-12-31100,000USD92
2024-07-01 to 2024-12-31100,000USD184
2023-10-01 to 2023-12-31300,000USD92
2023-07-01 to 2023-12-31600,000USD184

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2024-07-01 to 2024-12-312,766,000USD184
2023-07-01 to 2023-12-313,634,000USD184

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2024-10-01 to 2024-12-31921,000USD92
2024-07-01 to 2024-12-311,842,000USD184
2023-10-01 to 2023-12-31918,000USD92
2023-07-01 to 2023-12-311,842,000USD184

Nonoperating interest expense

Interest expense presented outside operating results. It differs from total interest expense when some borrowing cost is classified as operating or capitalized.

PeriodValueUnitDays
2024-10-01 to 2024-12-311,079,000USD92
2024-07-01 to 2024-12-312,073,000USD184
2023-10-01 to 2023-12-311,266,000USD92
2023-07-01 to 2023-12-312,549,000USD184

Other nonoperating income or expense

Other income or expense outside operations under this concept. The composition is filer-specific and can include one-time items.

PeriodValueUnitDays
2024-10-01 to 2024-12-31140,000USD92
2024-07-01 to 2024-12-31682,000USD184
2023-10-01 to 2023-12-3196,000USD92
2023-07-01 to 2023-12-31680,000USD184

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2024-07-01 to 2024-12-31752,000USD184
2023-07-01 to 2023-12-312,170,000USD184

Income taxes paid, net

Cash income taxes paid net of refunds during the period. It differs from income tax expense and can reflect prior years and estimated payments.

PeriodValueUnitDays
2024-07-01 to 2024-12-311,419,000USD184
2023-07-01 to 2023-12-31432,000USD184

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

PeriodValueUnitDays
2024-07-01 to 2024-12-31606,000USD184
2023-07-01 to 2023-12-31697,000USD184

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-12-311,794,000USD184
2023-07-01 to 2023-12-311,566,000USD184

Change in inventories

The cash flow adjustment for the change in inventories during the period. A positive value under this concept means inventory grew and reduced operating cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-12-31-961,000USD184
2023-07-01 to 2023-12-311,805,000USD184

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2024-07-01 to 2024-12-311,329,000USD184
2023-07-01 to 2023-12-31-3,062,000USD184

Inspect the source

Entity
AYTU BIOPHARMA, INC / CIK 0001385818
Captured
2026-09-20T07:58:53.461Z
SEC response SHA-256
3b664ab8156647d48cbdda6c8eb0b5f1ac4147c50f45c9bb53fa74b58565a69b

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001385818.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))